Teknova Reports Third Quarter 2026 Financial Results
Higher margins and lower cash outflow accompanied the raised revenue outlook, while October’s equity financing added cash and shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alpha Teknova (Nasdaq: TKNO) reported third-quarter 2026 revenue of $12.7 million, with higher sales and a narrower net loss. Revenue rose 22% year over year; Lab Essentials grew 9% and Clinical Solutions grew 86%. Gross margin increased to 38.0% from 30.7%. Net loss narrowed to $3.5 million, or $0.06 per diluted share, from $4.3 million, or $0.08 per diluted share.
Teknova raised its 2026 revenue outlook to $46 million to $48 million and continues to expect free cash outflow below $8 million. Quarterly free cash outflow declined to $1.4 million from $2.4 million, while operating expenses increased to $8.0 million from $7.2 million. Cash and short-term investments totaled $16.6 million at September 30. On October 22, Teknova completed an offering of 9,200,000 common shares at $5.00 each, raising $46.0 million gross and approximately $42.9 million net.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Teknova raised expected fiscal 2026 revenue to $46 million to $48 million.
- Major pointOctober 22 equity offering raised approximately $42.9 million net, with $46.0 million gross proceeds. 10% of market cap
- Moderate pointThird-quarter revenue rose 22% to $12.7 million from $10.5 million a year earlier.
- Moderate pointThird-quarter gross profit rose to $4.826 million from $3.206 million; margin increased to 38.0% from 30.7%.
- Moderate pointThird-quarter net loss narrowed to $3.490 million from $4.286 million; diluted loss per share fell to $0.06 from $0.08.
- Moderate pointThird-quarter adjusted EBITDA, an adjusted earnings measure, improved to negative $1.0 million from negative $1.6 million.
- Moderate pointThird-quarter operating cash use declined to $1.278 million from $1.980 million a year earlier.
- Moderate pointThird-quarter free cash outflow declined to $1.4 million from $2.4 million a year earlier.
7 minor points
- Minor pointClinical Solutions third-quarter revenue increased 86% to $3.2 million from $1.7 million year over year.
- Minor pointLab Essentials third-quarter revenue increased 9% to $9.0 million from $8.3 million year over year.
- Minor pointOther third-quarter revenue increased to $502,000 from $440,000 a year earlier.
- Minor pointNine-month revenue increased to $35.966 million from $30.536 million a year earlier.
- Minor pointNine-month gross profit increased to $13.495 million from $10.197 million a year earlier.
- Minor pointNine-month net loss narrowed to $11.215 million from $12.501 million; diluted loss per share fell to $0.21 from $0.23.
- Minor pointNine-month operating cash use declined to $5.108 million from $8.184 million a year earlier.
Negative
- Major pointEquity offering issued 9,200,000 common shares at $5.00 each, diluting existing holders.
- Moderate pointThird-quarter operating expenses rose to $8.032 million from $7.223 million a year earlier.
- Moderate pointCash and short-term investments declined to $16.560 million at September 30 from $21.338 million at December 31.
- Minor pointNine-month operating expenses increased to $23.889 million from $22.564 million a year earlier.
- Minor pointLong-term debt, net, increased to $13.269 million at September 30 from $13.123 million at December 31.
2 minor points
- Minor pointThird-quarter net interest expense increased to $259,000 from $190,000 a year earlier.
- Minor point. Forward-looking: it has not happened yet and may not happen.Teknova continues to expect fiscal 2026 free cash outflow of less than $8 million.
Key Figures
- Q3 revenue
- $12.7 million; up 22% year over year
- Third quarter 2026
- 2026 revenue guidance
- $46 million to $48 million
- Raised fiscal 2026 outlook
- 2026 Free Cash Outflow outlook
- Less than $8 million
- Fiscal 2026 outlook reaffirmed
- Public offering gross proceeds
- $46.0 million
- Underwritten public offering completed in October 2026
- Offering shares and price
- 9,200,000 shares at $5.00 per share
- Underwritten public offering
- Gross margin
- 38.0%
- Third quarter 2026, compared with 30.7% in third quarter 2025
- Adjusted EBITDA
- Negative $1.0 million
- Third quarter 2026, compared with negative $1.6 million in third quarter 2025
- Free Cash Outflow
- $1.4 million
- Third quarter 2026, compared with $2.4 million in third quarter 2025
Previous Earnings Reports
-
Reported year-over-year revenue growth and raised the 2026 revenue outlook.
-
Reported year-over-year revenue growth and reaffirmed the 2026 revenue outlook.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
adjusted ebitda financial
free cash flow financial
non-gaap financial
underwritten public offering financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Third quarter 2026 total revenue was
Company raises 2026 revenue guidance to
Strengthened balance sheet with
HOLLISTER, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2026.
“We posted record revenue for the second consecutive quarter,” said Stephen Gunstream, President and Chief Executive Officer at Teknova. “Growth was driven by increased sales of products to life science tools and diagnostics, and to biopharma customers. Notably, there was an increase in purchases of our custom products by small and mid-sized biotech customers and their associated contract manufacturers, which we believe is an early indication of biotech funding improvements over the past four quarters.”
Matt Lowell, Teknova’s Chief Financial Officer, added, “We delivered excellent financial results in the third quarter 2026 compared to 2025, highlighted by
Corporate and Financial Updates
- Third quarter 2026 total revenue of
$12.7 million , up22% compared to$10.5 million for the third quarter 2025 - On October 22, 2026, closed an underwritten public offering of 9,200,000 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of
$5.00 per share, for gross proceeds of$46.0 million and net proceeds of approximately$42.9 million - Total cash and short-term investments were
$16.6 million and total borrowings were$13.2 million at the end of the third quarter 2026 - Expanded its modular manufacturing platform with the launch of the Fill-Tek™ Dispensing System, which provides greater flexibility for customers to order the exact single-use bag sizes, quantities, and fill volumes their process requires across RUO, RUO+, and GMP grades, with no added turnaround time
Revenue for the Third Quarter 2026
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||
| (Dollars in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||
| Lab Essentials | $ | 9,034 | $ | 8,308 | $ | 26,613 | $ | 24,217 | |||||||
| Clinical Solutions | 3,168 | 1,706 | 7,741 | 4,928 | |||||||||||
| Other | 502 | 440 | 1,612 | 1,391 | |||||||||||
| Total revenue | $ | 12,704 | $ | 10,454 | $ | 35,966 | $ | 30,536 | |||||||
Third Quarter 2026 Financial Results
Total revenue for the third quarter 2026 was
Gross profit for the third quarter 2026 was
Operating expenses for the third quarter 2026 were
Net loss for the third quarter 2026 was
Cash used in operating activities for the third quarter 2026 was
A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.
2026 Outlook
Teknova raises its fiscal 2026 outlook for revenue and reaffirms its fiscal 2026 outlook for Free Cash Outflow. The Company now anticipates total revenue of
Upcoming Investor Conference Attendance
Craig-Hallum Alpha Select Conference (New York, NY)
November 17, 2026
Stephens Annual Investment Conference (Nashville, TN)
November 18, 2026
Conference Call and Webcast
Teknova will host a webcast and conference call on Wednesday, November 4, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.
Non-GAAP Financial Measures
This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of its business and the effectiveness of its business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow (Outflow).
Teknova defines Adjusted EBITDA as net income (loss) adjusted for interest income (expense), net, provision for (benefit from) income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representative of its ongoing operating performance.
Teknova defines Free Cash Flow (Outflow) as cash provided by (used in) operating activities less purchases of property, plant, and equipment.
Teknova provides Adjusted EBITDA and Free Cash Flow (Outflow) in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova’s industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova’s operating results because they exclude items that are not indicative of Teknova’s core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.
A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to Teknova’s anticipated total revenue, including our expectations for 2026 revenue and Free Cash Outflow guidance, and other statements about Teknova’s business prospects, including about Teknova’s profitability, strategy of managing operating expenses, and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, demand for Teknova’s products (including the potential delay to or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the conflicts in Ukraine and the Middle East; potential acquisitions and integration of other companies; and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which Teknova makes only as of the date hereof, even if they are repeated by Teknova subsequently. Teknova does not intend and shall have no obligation to update, amend, or clarify these forward-looking statements, except as may be required under applicable securities laws.
Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
| ALPHA TEKNOVA, INC. Condensed Statements of Operations (Unaudited) (In thousands, except share and per share data) | |||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenue | $ | 12,704 | $ | 10,454 | $ | 35,966 | $ | 30,536 | |||||||
| Cost of sales | 7,878 | 7,248 | 22,471 | 20,339 | |||||||||||
| Gross profit | 4,826 | 3,206 | 13,495 | 10,197 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 581 | 542 | 1,744 | 1,675 | |||||||||||
| Sales and marketing | 2,348 | 1,747 | 6,598 | 4,960 | |||||||||||
| General and administrative | 4,816 | 4,647 | 14,686 | 15,068 | |||||||||||
| Amortization of intangible assets | 287 | 287 | 861 | 861 | |||||||||||
| Total operating expenses | 8,032 | 7,223 | 23,889 | 22,564 | |||||||||||
| Loss from operations | (3,206 | ) | (4,017 | ) | (10,394 | ) | (12,367 | ) | |||||||
| Other expenses, net | |||||||||||||||
| Interest expense, net | (259 | ) | (190 | ) | (730 | ) | (499 | ) | |||||||
| Other adjustment to loan exit fee | — | — | — | 485 | |||||||||||
| Other income | 9 | — | 20 | — | |||||||||||
| Total other expenses, net | (250 | ) | (190 | ) | (710 | ) | (14 | ) | |||||||
| Loss before income taxes | (3,456 | ) | (4,207 | ) | (11,104 | ) | (12,381 | ) | |||||||
| Provision for income taxes | 34 | 79 | 111 | 120 | |||||||||||
| Net loss | $ | (3,490 | ) | $ | (4,286 | ) | $ | (11,215 | ) | $ | (12,501 | ) | |||
| Net loss per share—basic and diluted | $ | (0.06 | ) | $ | (0.08 | ) | $ | (0.21 | ) | $ | (0.23 | ) | |||
| Weighted average shares used in computing net loss per share—basic and diluted | 53,694,378 | 53,516,986 | 53,641,532 | 53,462,768 | |||||||||||
| ALPHA TEKNOVA, INC. Condensed Balance Sheets (Unaudited) (In thousands) | |||||||
| As of September 30, | As of December 31, | ||||||
| 2026 | 2025 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 6,631 | $ | 5,912 | |||
| Short-term investments, held-to-maturity | 9,929 | 15,426 | |||||
| Accounts receivable, net | 5,820 | 4,618 | |||||
| Inventories, net | 7,477 | 7,054 | |||||
| Prepaid expenses and other current assets | 1,942 | 1,501 | |||||
| Total current assets | 31,799 | 34,511 | |||||
| Property, plant, and equipment, net | 38,086 | 41,733 | |||||
| Operating right-of-use lease assets | 12,641 | 14,112 | |||||
| Intangible assets, net | 11,082 | 11,943 | |||||
| Other non-current assets | 1,076 | 1,285 | |||||
| Total assets | $ | 94,684 | $ | 103,584 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,813 | $ | 1,378 | |||
| Accrued liabilities | 5,111 | 4,283 | |||||
| Current portion of operating lease liabilities | 2,002 | 1,876 | |||||
| Total current liabilities | 8,926 | 7,537 | |||||
| Deferred tax liabilities | 989 | 879 | |||||
| Long-term debt, net | 13,269 | 13,123 | |||||
| Long-term operating lease liabilities | 11,716 | 13,270 | |||||
| Total liabilities | 34,900 | 34,809 | |||||
| Stockholders’ equity: | |||||||
| Preferred stock | — | — | |||||
| Common stock | 1 | 1 | |||||
| Additional paid-in capital | 206,788 | 204,564 | |||||
| Accumulated deficit | (147,005 | ) | (135,790 | ) | |||
| Total stockholders’ equity | 59,784 | 68,775 | |||||
| Total liabilities and stockholders’ equity | $ | 94,684 | $ | 103,584 | |||
| ALPHA TEKNOVA, INC. Condensed Statements of Cash Flows (Unaudited) (In thousands) | |||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Operating activities: | |||||||||||||||
| Net loss | $ | (3,490 | ) | $ | (4,286 | ) | $ | (11,215 | ) | $ | (12,501 | ) | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||||||
| Bad debt expense | 3 | 22 | 8 | 71 | |||||||||||
| Inventory reserve | 355 | 732 | 1,180 | 1,657 | |||||||||||
| Depreciation and amortization | 1,589 | 1,591 | 4,758 | 4,761 | |||||||||||
| Stock-based compensation | 612 | 850 | 1,929 | 2,652 | |||||||||||
| Deferred taxes | 33 | 78 | 110 | 119 | |||||||||||
| Accrued interest income on short-term investments | 19 | (62 | ) | 26 | (8 | ) | |||||||||
| Amortization of discount on short-term investments | (92 | ) | (153 | ) | (237 | ) | (508 | ) | |||||||
| Amortization of debt financing costs | 51 | 44 | 146 | 173 | |||||||||||
| Other adjustment to loan exit fee | — | — | — | (485 | ) | ||||||||||
| Non-cash lease expense | 14 | 31 | 43 | 92 | |||||||||||
| Loss on disposal of property, plant, and equipment | 68 | — | 92 | 19 | |||||||||||
| Changes in operating assets and liabilities: | |||||||||||||||
| Accounts receivable | (415 | ) | (17 | ) | (1,210 | ) | (894 | ) | |||||||
| Inventories | (921 | ) | (36 | ) | (1,603 | ) | (1,770 | ) | |||||||
| Prepaid expenses and other current assets | (1,181 | ) | (1,424 | ) | (869 | ) | (1,464 | ) | |||||||
| Other non-current assets | 51 | 33 | 209 | 67 | |||||||||||
| Accounts payable | 350 | (136 | ) | 508 | 244 | ||||||||||
| Accrued liabilities | 1,676 | 753 | 1,017 | (399 | ) | ||||||||||
| Other | — | — | — | (10 | ) | ||||||||||
| Cash used in operating activities | (1,278 | ) | (1,980 | ) | (5,108 | ) | (8,184 | ) | |||||||
| Investing activities: | |||||||||||||||
| Purchases of short-term investments | (3,924 | ) | (3,973 | ) | (11,792 | ) | (13,708 | ) | |||||||
| Maturities of short-term investments | 5,500 | 6,000 | 17,500 | 22,000 | |||||||||||
| Purchases of property, plant, and equipment | (120 | ) | (387 | ) | (466 | ) | (800 | ) | |||||||
| Cash provided by investing activities | 1,456 | 1,640 | 5,242 | 7,492 | |||||||||||
| Financing activities: | |||||||||||||||
| Proceeds from long-term debt | — | — | — | 1,110 | |||||||||||
| Payment of exit fee costs | — | — | — | (1,110 | ) | ||||||||||
| Proceeds from financed insurance premiums | 428 | 333 | 428 | 333 | |||||||||||
| Repayment of financed insurance premiums | (41 | ) | (94 | ) | (138 | ) | (150 | ) | |||||||
| Proceeds from exercise of stock options | 62 | 29 | 241 | 49 | |||||||||||
| Proceeds from issuance of common stock under employee stock purchase plan | — | — | 54 | 56 | |||||||||||
| Payment of debt issuance costs | — | — | — | (100 | ) | ||||||||||
| Cash provided by financing activities | 449 | 268 | 585 | 188 | |||||||||||
| Change in cash and cash equivalents | 627 | (72 | ) | 719 | (504 | ) | |||||||||
| Cash and cash equivalents at beginning of period | 6,004 | 3,276 | 5,912 | 3,708 | |||||||||||
| Cash and cash equivalents at end of period | $ | 6,631 | $ | 3,204 | $ | 6,631 | $ | 3,204 | |||||||
| ALPHA TEKNOVA, INC. Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (Unaudited) (In thousands) | |||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net loss – as reported | $ | (3,490 | ) | $ | (4,286 | ) | $ | (11,215 | ) | $ | (12,501 | ) | |||
| Add back: | |||||||||||||||
| Interest expense, net | (259 | ) | (190 | ) | (730 | ) | (499 | ) | |||||||
| Provision for income taxes | 34 | 79 | 111 | 120 | |||||||||||
| Depreciation expense | 1,302 | 1,304 | 3,897 | 3,900 | |||||||||||
| Amortization of intangible assets | 287 | 287 | 861 | 861 | |||||||||||
| EBITDA | $ | (1,608 | ) | $ | (2,426 | ) | $ | (5,616 | ) | $ | (7,121 | ) | |||
| Other and non-recurring expenses: | |||||||||||||||
| Stock-based compensation expense | 612 | 850 | 1,929 | 2,652 | |||||||||||
| Other adjustment to loan exit fee | — | — | — | (485 | ) | ||||||||||
| Adjusted EBITDA | $ | (996 | ) | $ | (1,576 | ) | $ | (3,687 | ) | $ | (4,954 | ) | |||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Cash used in operating activities | $ | (1,278 | ) | $ | (1,980 | ) | $ | (5,108 | ) | $ | (8,184 | ) | |||
| Purchases of property, plant, and equipment | (120 | ) | (387 | ) | (466 | ) | (800 | ) | |||||||
| Free Cash Flow | $ | (1,398 | ) | $ | (2,367 | ) | $ | (5,574 | ) | $ | (8,984 | ) | |||
This press release was published by a CLEAR® Verified individual.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is Teknova’s updated 2026 revenue guidance?
Teknova now expects fiscal 2026 revenue of $46 million to $48 million. It raised its revenue outlook while maintaining expected free cash outflow of less than $8 million for the year ending December 31, 2026.
How much did Teknova raise in its October 2026 stock offering?
Teknova raised $46.0 million in gross proceeds and approximately $42.9 million in net proceeds. The offering closed October 22, 2026, with 9,200,000 common shares sold at $5.00 each, including full exercise of the underwriters’ option to purchase additional shares.
Why did Teknova’s third-quarter 2026 gross margin improve?
Teknova attributed the margin improvement primarily to higher revenue and, to a lesser extent, lower fixed-cost absorption into cost of goods sold from changes in finished-goods inventory levels. Higher variable costs partially offset those effects.
Why did Teknova’s third-quarter 2026 operating expenses increase?
Teknova attributed the increase primarily to higher sales and marketing spending from higher headcount, alongside slightly higher general and administrative expenses. Lower stock-based compensation expense partially offset these increases.